Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200
Diffuse large B-cell lymphoma (DLBCL) is treated with an expanding range of antibody- and cell-based therapies, yet macrophage phagocytosis checkpoints are still often discussed one molecule at a time. Here, we ask how far the evidence for each major axis has actually progressed in DLBCL immunotherapy. We considered fi...